Meribel Pharma Solutions, a new mid-sized CDMO, has launched with an extensive integrated network across Europe, led by a team of industry experts on a mission “to deliver the highest quality solutions and services to enable customers to scale to new heights and improve patient health.”

The firm has ten manufacturing sites and three drug development services sites situated across France, Spain and Sweden. It is headed up by CEO, Bruce Vielle, formerly President, CEO of Synerlab, and COO, Steve Leonard, who joins the firm from Integra Life Sciences where he was Corporate VP, Global Operations & Supply Chain. Prior to that, he was SVP, Head of Global Operations at Catalent.

Built on a legacy of expertise in oral solid dose (OSD) manufacturing, semi-solid dosage formulations, and sterile drug products, the firm has established centers of excellence in drug development, lyophilization, preservative-free multidose technologies, and flexible stick-pack and sachet production. From concept to commercialization, Meribel Pharma Solutions can deliver niche technical expertise at every stage of the drug development journey.

Meribel Pharma Solutions CEO, Bruce Vielle said: “There is a gap in the market for a niche-player, mid-sized CDMO that’s focused, agile, and dedicated to solving complex challenges, and we are well positioned to fulfill this unmet need.

“We have invested heavily in the latest technologies and expanded our capacity to meet the evolving needs of our customers. As a unified organization, our foundations are built on quality and reliability. We bring together greater resources, deeper expertise, and enhanced agility, enabling us to meet our customers’ requirements better than ever before.”

The name Meribel Pharma Solutions is inspired by the Meribel mountain range in the Alps. The name symbolizes the firm bringing together manufacturing excellence from across three countries: France, Spain, and Sweden. It is also a nod to the firm’s commitment to helping customers navigate complex challenges and reach new heights in drug development and manufacturing.